A Phase 1 interventional study of VIR-2218 in Renal Impairment, sponsored by Vir Biotechnology, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.
Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 267th largest by enrollment of the 468 interventional ones that give a count, is one of 21 that started in 2023, is one of 232 in phase 1, and was the 485th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–80 · Healthy volunteers
Sanofi · Sites in United States
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in United States
Ages 18–85 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
553 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 247 · Phase 2 71 · Phase 3 53 · Phase 4 44
First in 1990; this study’s year is marked. 21 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 32 across the 468 interventional studies, 182 across the 82 observational. Of the 464 that completed or were terminated, 169 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
334 of 553 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
22 of the studies in Renal Insufficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT07341516Paris Translational Research Center for Organ TransplantationWorldwide Assessment of Deceased Donor Kidney Utilization | 2026-11 |
| NCT04605679Loma Linda UniversityHepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients | 2026-12 |
| NCT07857837ShionogiStudy of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | 2026-12-04 |
| NCT03099434Johns Hopkins UniversityExpanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media | 2026-12-07 |
Add all 22 to your calendar (.ics) → With an account.
Among the 553 studies in Renal Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.
Inclusion Criteria for All Participants:
Inclusion Criteria: Additional Criteria Specific to Healthy Participants:
Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
Exclusion Criteria: Criteria for All Participants
Exclusion Criteria: Additional Criteria Specific to Healthy Participants
Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VIR-2218
Drug: VIR-2218
VIR-2218 given by subcutaneous injection
Also known as: Elebsiran
Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Time frame: 4 days
Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Time frame: 4 days
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
Time frame: 4 days
Fraction Excreted in Urine in Percentage for VIR-2218
Time frame: 4 days
Amount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Renal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame: 4 days
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: 8 weeks
| Milestone | Cohort 1: Single Dose of VIR-2218 in Moderate Renal Impairment and Matched Healthy Participants | Cohort 2: Singe Dose of VIR-2218 in Severe Renal Impairment and Matched Healthy Participants |
|---|---|---|
| Started | 16 | 12 |
| Completed | 16 | 12 |
| Not completed | 0 | 0 |
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
| ng/mL | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| VIR-2218 Cmax | 319 ± 31.4 | 390 ± 13.2 | 584 ± 32.6 | 488 ± 19.9 |
| AS(N-1)3'VIR-2218 Cmax | 44.7 ± 42.4 | 49.5 ± 31.6 | 91.7 ± 52.3 | 59.3 ± 33.6 |
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
| h*ng/mL | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| VIR-2218 AUClast | 7140 ± 28.1 | 6590 ± 24.4 | 11100 ± 47.3 | 8240 ± 19.0 |
| AS(N-1)3'VIR-2218 AUClast | 1050 ± 34.2 | 812 ± 39.4 | 2020 ± 49.3 | 1080 ± 20.9 |
Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.
| h*ng/mL | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| VIR-2218 AUCinf | 7550 ± 31.7 | 6670 ± 30.3 | 11300 ± 47.2 | 8530 ± 19.0 |
| AS(N-1)3'VIR-2218 AUCinf | 1240 ± 35.3 | 1110 ± 46.0 | 2740 ± 36.2 | 1220 ± 29.0 |
| fe% | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| Fraction Excreted in Urine in Percentage for VIR-2218 | 9.18 ± 35.8 | 12.6 ± 36.6 | 4.96 ± 50.7 | 15.9 ± 30.1 |
| mg | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| VIR-2218 Ae | 18.4 ± 35.8 | 25.3 ± 36.6 | 9.91 ± 50.7 | 31.9 ± 30.1 |
| AS(N-1)3'VIR-2218 Ae | 4.09 ± 41.0 | 4.11 ± 36.1 | 2.22 ± 42.9 | 5.14 ± 31.0 |
| L/h | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| VIR-2218 CLR | 2.57 ± 20.2 | 3.83 ± 50.6 | 0.891 ± 76.9 | 3.87 ± 29.0 |
| AS(N-1)3'VIR-2218 CLR | 3.90 ± 19.8 | 5.06 ± 46.9 | 1.10 ± 79.3 | 4.78 ± 35.2 |
| Participants | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants |
|---|---|---|---|---|
| Participants with any TEAEs | 2 | 0 | 5 | 2 |
| Participants with any SAEs | 0 | 0 | 0 | 0 |
Collected over Up to 12 weeks. Non-serious events are listed at a 1.25% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Cohort 2: Singe Dose of VIR-2218 in 6 Severe Renal Impairment Participants | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 2: Singe Dose of VIR-2218 in 6 Healthy Matched Participants | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Singe Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Singe Dose of VIR-2218 in 6 Healthy Matched Participants |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 1/8 | 0/8 | 1/6 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 0/8 | 0/8 | 0/6 | 1/6 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/8 | 1/6 | 0/6 |
| ConstipationGastrointestinal disorders | 0/8 | 0/8 | 1/6 | 0/6 |
| Fibrin D dimer increasedInvestigations | 0/8 | 0/8 | 1/6 | 0/6 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/8 | 0/8 | 1/6 | 0/6 |
| Injection site haematomaGeneral disorders | 0/8 | 0/8 | 1/6 | 0/6 |
| Muscle strainMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 1/6 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 0/8 | 0/6 | 1/6 |
| CrystalluriaRenal and urinary disorders | 1/8 | 0/8 | 0/6 | 0/6 |
| Age, Categorical(Participants) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Participant Age — <=18 years | 0 | 0 | 0 | 0 | 0 |
| Participant Age — Between 18 and 65 years | 2 | 7 | 5 | 5 | 19 |
| Participant Age — >=65 years | 6 | 1 | 1 | 1 | 9 |
| Age, Continuous(years) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Cohort 1 Participant Ages | 64.6 ± 5.71 | 60.4 ± 4.24 | — | — | 62.5 ± 5.33 |
| Cohort 2 Participant Ages | — | — | 59.8 ± 6.55 | 57.2 ± 6.82 | 58.5 ± 6.53 |
| Sex: Female, Male(Participants) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Female | 6 | 6 | 4 | 4 | 20 |
| Male | 2 | 2 | 2 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 1 | 1 | 7 |
| White | 6 | 5 | 5 | 5 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| United States | 8 | 8 | 6 | 6 | 28 |
| Weight(kg) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Cohort 1 Weight | 94.7 ± 12.82 | 79.2 ± 5.3 | — | — | 86.9 ± 12.38 |
| Cohort 2 Weight | — | — | 98.5 ± 10.64 | 78.2 ± 6.64 | 88.3 ± 13.57 |
| BMI(kg/m^2) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Cohort 1 BMI | 31.2 ± 2.96 | 29.2 ± 3.32 | — | — | 30.2 ± 3.20 |
| Cohort 2 BMI | — | — | 32.0 ± 3.63 | 30.0 ± 4.72 | 31.0 ± 4.15 |
| eGFR(mL/min/1.73 m^2) | Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants | Cohort 1: Single Dose of VIR-2218 in 8 Healthy Matched Participants | Cohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment Participants | Cohort 2: Single Dose of VIR-2218 in 6 Healthy Matched Participants | Total |
|---|---|---|---|---|---|
| Cohort 1 eGFR | 49.38 ± 4.069 | 108.25 ± 17.244 | — | — | 78.81 ± 32.724 |
| Cohort 2 eGFR | — | — | 22.83 ± 4.579 | 100 ± 100.507 | 61.42 ± 41.033 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2023 to primary completion in Mar 2025, 21 months.
Results were first posted in Oct 2026, 1 year 7 months after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 21 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elebsiran